Fracture healing with alendronate treatment in the Brtl/ plus mouse model of osteogenesis imperfecta

被引:19
|
作者
Meganck, J. A. [1 ,2 ]
Begun, D. L. [1 ,2 ]
McElderry, J. D. [3 ]
Swick, A. [1 ,2 ]
Kozloff, K. M. [1 ,2 ]
Goldstein, S. A. [1 ,2 ]
Morris, M. D. [3 ]
Marini, J. C. [4 ]
Caird, M. S. [1 ]
机构
[1] Univ Michigan, Dept Orthopaed Surg, Orthopaed Res Labs, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA
[4] NICHHD, Bone & Extracellular Matrix Branch, NIH, Bethesda, MD 20892 USA
基金
美国国家科学基金会; 美国国家卫生研究院;
关键词
Osteogenesis imperfecta; Bisphosphonates; Bone; Rodent; Fracture repair; HYPERPLASTIC CALLUS FORMATION; POLARIZED-LIGHT MICROSCOPY; ZOLEDRONIC ACID; BISPHOSPHONATE INCADRONATE; BONE STRENGTH; CHILDREN; PAMIDRONATE; COLLAGEN; REPAIR; RATS;
D O I
10.1016/j.bone.2013.06.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Osteogenesis imperfecta (OI) is a heritable bone dysplasia characterized by increased skeletal fragility. Patients are often treated with bisphosphonates to attempt to reduce fracture risk. However, bisphosphonates reside in the skeleton for many years and long-term administration may impact bone material quality. Acutely, there is concern about risk of non-union of fractures that occur near the time of bisphosphonate administration. This study investigated the effect of alendronate, a potent aminobisphosphonate, on fracture healing. Using the Brtl/+ murine model of type IV OI, tibial fractures were generated in 8-week-old mice that were untreated, treated with alendronate before fracture, or treated before and after fracture. After 2, 3, or 5 weeks of healing, tibiae were assessed using microcomputed tomography (mu CT), torsion testing, quantitative histomorphometry, and Raman microspectroscopy. There were no morphologic, biomechanical or histomorphometric differences in callus between untreated mice and mice that received alendronate before fracture. Alendronate treatment before fracture did not cause a significant increase in cartilage retention in fracture callus. Both Brtl/+ and WT mice that received alendronate before and after fracture had increases in the callus volume, bone volume fraction and torque at failure after 5 weeks of healing. Raman microspectroscopy results did not show any effects of alendronate in wild-type mice, but calluses from Brtl+ mice treated with alendronate during healing had a decreased mineral-to-matrix ratio, decreased crystallinity and an increased carbonate-to-phosphate ratio. Treatment with alendronate altered the dynamics of healing by preventing callus volume decreases later in the healing process. Fracture healing in Brtl/+ untreated animals was not significantly different from animals in which alendronate was halted at the time of fracture. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:204 / 212
页数:9
相关论文
共 50 条
  • [31] Single dose of bisphosphonate preserves gains in bone mass following cessation of sclerostin antibody in Brtl/ plus osteogenesis imperfecta model
    Perosky, Joseph E.
    Khoury, Basma M.
    Jenks, Terese N.
    Ward, Ferrous S.
    Cortright, Kai
    Meyer, Bethany
    Barton, David K.
    Sinder, Benjamin P.
    Marini, Joan C.
    Caird, Michelle S.
    Kozloff, Kenneth M.
    BONE, 2016, 93 : 79 - 85
  • [32] Combination treatment with growth hormone and zoledronic acid in a mouse model of Osteogenesis imperfecta
    Lee, Lucinda R.
    Holman, Aimee E.
    Li, Xiaoying
    Vasiljevski, Emily R.
    O'Donohue, Alexandra K.
    Cheng, Tegan L.
    Little, David G.
    Schindeler, Aaron
    Biggin, Andrew
    Munns, Craig F.
    BONE, 2022, 159
  • [33] Alendronate treatment rescues the effects of compressive loading of TMJ in osteogenesis imperfecta mice
    Chen, Po-Jung
    Mehta, Shivam
    Dutra, Eliane H.
    Yadav, Sumit
    PROGRESS IN ORTHODONTICS, 2024, 25 (01):
  • [34] A Mouse Model for Human Osteogenesis Imperfecta Type VI
    Bogan, Rosalind
    Riddle, Ryan C.
    Li, Zhu
    Kumar, Sarvesh
    Nandal, Anjali
    Faugere, Marie-Claude
    Boskey, Adele
    Crawford, Susan E.
    Clemens, Thomas L.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2013, 28 (07) : 1531 - 1536
  • [35] Behavioral signs of pain and functional impairment in a mouse model of osteogenesis imperfecta
    Abdelaziz, Dareen M.
    Abdullah, Sami
    Magnussen, Claire
    Ribeiro-da-Silva, Alfredo
    Komarova, Svetlana V.
    Rauch, Frank
    Stone, Laura S.
    BONE, 2015, 81 : 400 - 406
  • [36] Respiratory defects in the CrtapKO mouse model of osteogenesis imperfecta
    Dimori, Milena
    Heard-Lipsmeyer, Melissa E.
    Byrum, Stephanie D.
    Mackintosh, Samuel G.
    Kurten, Richard C.
    Carroll, John L.
    Morello, Roy
    AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2020, 318 (04) : L592 - L605
  • [37] Mineral changes in a transgenic mouse model for osteogenesis imperfecta
    Cassella, JP
    Pereira, R
    Prockop, DJ
    Ali, SY
    BRITISH JOURNAL OF BIOMEDICAL SCIENCE, 1996, 53 (02) : 108 - 115
  • [38] Strontium Ranelate Reduces the Fracture Incidence in a Growing Mouse Model of Osteogenesis Imperfecta
    Shi, Changgui
    Hu, Bo
    Guo, Lei
    Cao, Peng
    Tian, Ye
    Ma, Jun
    Chen, Yuanyuan
    Wu, Huiqiao
    Hu, Jinquan
    Deng, Lianfu
    Zhang, Ying
    Yuan, Wen
    JOURNAL OF BONE AND MINERAL RESEARCH, 2016, 31 (05) : 1003 - 1014
  • [39] Tendon properties in a mouse model of severe osteogenesis imperfecta
    Sinkam, Larissa
    Boraschi-Diaz, Iris
    Svensson, Rene B.
    Kjaer, Michael
    Komarova, Svetlana V.
    Bergeron, Raynald
    Rauch, Frank
    Veilleux, Louis-Nicolas
    CONNECTIVE TISSUE RESEARCH, 2023, 64 (03) : 285 - 293
  • [40] Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate
    Munns, CFJ
    Rauch, F
    Zeitlin, L
    Fassier, F
    Glorieux, FH
    JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (11) : 1779 - 1786